Close this search box.

Public equity report: Soleno, Abeona raise capital for late-stage rare disease programs

ARTICLE | Finance

Plus a $100M PIPE for cancer play Context Therapeutics

By Stephen Hansen, Director of Biopharma Intelligence

May 3, 2024 6:05 PM UTC

Two rare disease biotechs raised substantial capital to help finance regulatory and commercial preparations for late-stage programs.

Soleno Therapeutics Inc. (NASDAQ:SLNO) announced after market close on Thursday that it had raised $138 million through the sale of 3 million shares at $46 per share — a 7% discount to Thursday’s close of $49.23…